Immunocore of Abingdon, UK, secured a record $320 million in a series A round in July. It is Europe's largest-ever venture round and the second biggest worldwide, behind Moderna Therapeutics' $450 million raised in January (Nat. Biotechnol. 33, 199, 2015). New investors Woodford Investment Management, Malin Crop and Eli Lilly participated alongside undisclosed existing investors. Immunocore said it will use the funding to accelerate its pipeline of therapeutics called ImmTACS. These are a new class of bispecific molecules that combine a monoclonal T-cell receptor fused to an anti-CD3 antibody fragment that recruits T cells to the tumor. Immunocore's lead candidate IMCgp100 is in phase 2a testing for late-stage melanoma. The company has already signed partnerships with Lilly, Genentech, GlaxoSmithKline and MedImmune.